Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Organisation › Details

Sloning BioTechnology GmbH

https://www.sloning.com

	Start	2000-01-01 established
	Group	MorphoSys (Group)
	Industry	synthetic genome
	Industry 2	protein engineering

	Region	Puchheim
	Country	Germany
	Street	4 Zeppelinstr.
	City	82178 Puchheim
	Tel	+49-89-809095-0
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2007-10-18)


		Record changed: 2023-12-30

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for MorphoSys (Group)

[1] MorphoSys AG. (2/5/24). "Press Release: MorphoSys Enters into Business Combination Agreement to Be Acquired by Novartis for € 2.7 Billion Equity Value. Tafasitamab Sold to Incyte". Planegg....
[2] MorphoSys AG. (12/14/23). "Press Release: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million [Not for US, AU, ZA, JP, et al.]". Planegg....
[3] MorphoSys AG. (5/3/23). "Press Release: MorphoSys AG Reports First Quarter 2023 Financial Results". Planegg....
[4] MorphoSys AG. (3/14/23). "Press Release: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer". Planegg....
[5] MorphoSys AG. (3/2/23). "Press Release: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs". Planegg....
[6] MorphoSys AG. (12/20/22). "Press Release: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023". Planegg....
[7] MorphoSys AG. (12/6/22). "Press Release: MorphoSys Out Licenses Pre-Clinical Oncology Program". Planegg....
[8] MorphoSys AG. (11/14/22). "Press Release: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease". Planegg....
[9] Roche. (11/14/22). "Press Release: Roche Provides Update on Phase III GRADUATE Programme Evaluating Gantenerumab in Early Alzheimer’s Disease". Basel....
[10] MorphoSys AG. (10/27/22). "Press Release: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis". Planegg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]